cys (Total 126 Patents Found)

Cys (126 Patents Found)
The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueo...
The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueo...
The invention comprises a preparation of X-S-Cys-X, moiety, BRAUNMYCIN Î>>, where X maybe naturally linked peptide or glycan residues essential for iron-reductase activity, as well as methods of obtaining preparation from an iron-nitriloacetic acid iron binding jaw, BRAUNMYCIN8567, a component of a batch affinit...
PEG-IFN-β conjugates, where a PEG moiety is covalently bound to Cys 17 of human IFN-β, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. Th...
The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueo...
La présente invention concerne des méthodes et des compositions pour le traitement, le diagnostic et la prévention de maladies, telles que les maladies néoplasiques, les maladies neurodégénératives, les maladies cardiovasculaires, les maladies auto-immunes et les maladies inflammatoires. Lesdites méthodes font ...
The present invention provides methods and compositions for the treatment, diagnosis, and prevention of diseases, such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods include the administration of pharmaceutical complexes comprisin...
The instant invention relates to single domain antibodies directed against a Cys-loop receptor, preferably 5-HT3 receptor. Said single -domain antibodies have a dissociation constant Kd for the Cys-loop receptor of at least 10 -6 M and can modulate its activity. The invention also relates to a method for obtaining sai...
The invention belongs to the development technical field of single photon emission computed tomography (SPECT) and in particular relates to a Cys-Annexin V kit used for 99mTc labeling, a preparation method and application thereof in apoptosis detection. Each kit provided by the invention is prepared as follows: 25-150u...
La présente invention concerne l'utilisation du composé peptidique Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH en tant qu'agent thérapeutique pour la prophylaxie et/ou le traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neur...
The invention relates to isolated cytolytic T cells which recognize complexes of HLA-B35 molecules and the peptide defined by SEQ ID NO: 2, as well as methods for identifying HLA-B35 positive cells. The method involves contacting the cytolytic T cells to a sample, and determining activity of these cytolytic T cells....
本发明的18F标记Cys‑Annexin V的方法,采用18F‑FBEM标记Cys‑Annexin V,标记率高、可实现18F定位标记Cys‑Annexin V,且标记后的18F‑FBEM‑Cys‑Annexin V与PS保持良好的亲和性,作为PET显像剂可实现良好的显像效果,具有较为理想的显像特异性。...
Various specific human SP-18 and human SP-5 derived peptides have alveolar surfactant protein (ASP) activity. These peptides are prepared using synthetic methods or by recombinant techniques. The peptides of the invention include surfactant proteins having serine replacements for the cysteines....
The invention belongs to the technical field of SPECT (single photon emission computed tomography) development, and particularly relates to a method for marking Cys-Annexin V by use of 99mTc, and an application of 99mTc-Cys-Annexin V in detecting cell apoptosis as a developer. The method for marking Cys-Annexin V by us...
La présente invention concerne l'utilisation du composé peptidique His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe en tant qu'agent thérapeutique destiné à la prophylaxie et/ou au traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodégén...
In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA i...
The invention discloses a preparation method and an application of a boron-dipyrromethene (BODIPY) based fluorescent probe for determining cysteine (Cys). The structural formula of the probe is shown in the specification. The preparation method of the BODIPY derivative based Cys fluorescent probe with a simple structur...
In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA i...
The invention discloses a novel synthesis method of a L-Ser L-Cys pseudo dipeptide with a basic peptide module. The method comprises the following steps: firstly, preparing white solid L-Ser-OMe.HC1 by utilizing L-Ser; preparing white solid L-Ser(tBu)-OMe.TsOH solid by utilizing the L-Ser-OMe.HC1; preparing Fmoc-L-Ser(...
The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueo...
The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, h...
The invention discloses Arg-Leu-Val-Cys-Val and discloses a preparation method, analgesic activity, antitumor activity, antithrombotic activity and thrombolytic activity thereof. Therefore, the invention discloses application of the Arg-Leu-Val-Cys-Val in the preparation of analgesic drugs, antitumor drugs, antithrombo...
The present invention is directed to the use of the peptide compound Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung ...
La présente invention concerne des méthodes et des compositions pour le traitement, le diagnostic et la prévention de maladies, telles que les maladies néoplasiques, les maladies neurodégénératives, les maladies cardiovasculaires, les maladies auto-immunes et les maladies inflammatoires. Lesdites méthodes font ...
La présente invention concerne l'utilisation du composé peptidique Pro-Gly-Thr-Cys-Glu-lle-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH en tant qu'agent thérapeutique pour la prophylaxie et/ou le traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodé...
The present invention is directed to the use of the peptide compound Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH or its combination with the peptide Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, in...
The present invention is directed to the use of the peptide compound Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH or its combination with the peptide Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, in...
La présente invention concerne la séquence d'un récepteur matriciel de cellule, spécifique de la région Cys-Ser-Val-Thr-Cys-Gly (SEQ ID NO:1) de la thrombospondine. L'invention concerne également la purification, le clonage et des procédés d'expression. La protéine réceptrice est utilisée dans de...
La présente invention concerne la séquence d'un récepteur matriciel de cellule, spécifique de la région Cys-Ser-Val-Thr-Cys-Gly (SEQ ID NO:1) de la thrombospondine. L'invention concerne également la purification, le clonage et des procédés d'expression. La protéine réceptrice est utilisée dans de...
La présente invention concerne l'utilisation du composé peptidique Pro-Gly-Thr-Cys-Glu-lle-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH en tant qu'agent thérapeutique pour la prophylaxie et/ou le traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodé...
1. A compound according to the formula below is provided wherein R 1 and R 2 are independently selected from the group consisting of H, an anionic group and a reactive group, which is either an ethylenically unsaturated polymerizable group selected from the group consisting of acryloyl, methacryloyl, a...
In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA i...
La présente invention concerne des compositions et des procédés permettant de déterminer le niveau de molécules contenant du thiol et du disulfure dans un échantillon. Les compositions et les procédés peuvent être utilisés pour déterminer le niveau de stress oxydatif chez un sujet recevant ou non un traiteme...
Compositions and methods for determining the level of thiol and disulfide containing molecules in a sample are provided. The compositions and methods can be used to determine the level of oxidative stress in a subject with or without antioxidant treatment. Also provided are biomarkers of oxidative stress....
The present invention provides the sequence of a cell matrix receptor specific for the Cys-Ser-Val-Thr-Cys-Gly (SEQ ID NO:1) region of thrombospondin. Also provided are purification, cloning and expression methods. The receptor protein is useful in numerous diagnostic, prophylactic and therapeutic areas....